secwatch.observer — SEC 8-K summary
======================================

Issuer:     Stoke Therapeutics, Inc. (STOK)
CIK:        0001623526
Form:       8-K
Filed at:   2025-02-18T23:59:59+00:00
Accession:  0001193125-25-028650
Event type: m_and_a
Sentiment:  positive
Materiality: 0.85
Item codes: 1.01, 7.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Stoke and Biogen enter $165M upfront collaboration for zorevunersen (Dravet syndrome)
--------------------------------------------------------------------------------

- Stoke receives $165M upfront; eligible for up to $385M in milestones and low-double-digit to high-teen royalties.
- Stoke retains exclusive rights in US, Canada, Mexico; Biogen gets rest-of-world commercialization rights.
- Phase 3 EMPEROR study to start Q2 2025 with pivotal data readout expected 2H 2027.
- Cash runway extended to mid-2028, including upfront payment and other eligible cash flows.
- Zorevunersen has FDA Breakthrough Therapy designation; Phase 1/2a showed substantial seizure reduction and cognitive improvements.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1623526/000119312525028650/0001193125-25-028650-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1623526/000119312525028650/d889348d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-25-028650

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer